Myeloma Center

You are here

Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.

TitlePreclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Publication TypeJournal Article
Year of Publication2014
AuthorsMark TM, Coleman M, Niesvizky R
JournalLeuk Res
Volume38
Issue5
Pagination517-24
Date Published2014 May
ISSN1873-5835
KeywordsAngiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Multiple Myeloma, Recurrence, Thalidomide
Abstract

Despite the evolution of effective frontline treatment strategies, many patients with myeloma inevitably relapse. Treatment can be complicated by the interplay of disease-, treatment-, and patient-related factors. Unfortunately, many patients eventually develop disease that is refractory to lenalidomide and bortezomib and have few treatment options. Pomalidomide is a distinct IMiD agent recently approved in the US and Europe. We review the pomalidomide mechanism of action, summarizing its direct antimyeloma, immunomodulatory, and stromal-support inhibitory activities. We also detail its clinical development, including establishment of the approved dose/schedule, phase 2 and 3 trials in relapsed and refractory patients, and novel pomalidomide-based combinations.

DOI10.1016/j.leukres.2014.02.008
Alternate JournalLeuk. Res.
PubMed ID24690110